Biological E Plans To Invest 1800 Crores In Hyderabad To Manufacture Vaccines.

With an investment of over INR 1800 crores and the creation of more than 2500 jobs in their three facilities at Genome Valley, Biological E cements Hyderabad's position as the "Vaccine Capital of the World".

The expansion is primarily targeted to ramp up the manufacturing of vaccines, generic injectables, and R&D.

The announcement was made after Minister KTR met with Biological E Mahima Datla, M.D.

Hyderabad accounts for 1/3rd of global vaccine production with a capacity of about 9 bn doses per annum. This investment from Biological E will enhance the capacity by 5 bn doses increasing the cumulative capacity to about 14 bn doses each year, further consolidating the leadership of Hyderabad in vaccines.

Investment will be focused on manufacturing of Janssen Covid vaccine, MR Vaccine, Typhoid Vaccine, Covid Vaccine, PCV Vaccine, Tetanus Toxide Ampoules, IPV Vaccine and Pertussis Vaccine, biological APIs and formulations, speciality Generic Injectables and R&D with a cumulative investment of INR 1801 crores and employment potential of 2518 people.

All of these activities will be located in Genome Valley with world-class infrastructure facilities in the form of Special Economic Zones (SEZs), Industrial / Knowledge Parks, Multi-tenanted dry and wet laboratories and incubation facilities. It is home to over 200 companies with a scientific workforce of approximately 15,000 professionals.